7:00 am Coffee & Registration

8:00 am Chair’s Welcoming Remarks

8:05 am
Assessing The Strategic Value Of 3D Models

8:10 am From Validation to Application How 3D Models Have Been Supporting GSK IO & Oncology Programs

Synopsis

  • Highlighting opportunities and challenges in adoption of 3D solid tumor models in preclinical drug discovery
  • How do we validate, scale and automate 3D solid tumor models in preclinical drug discovery?
  • Methods to evaluate and validate new technologies for advanced 3D in vitro immuno-oncology models

8:40 am Beyond 3D-Models – Building Confidence in Microphysiological Models at Novartis

Synopsis

  • Divulging Novartis’ approach to 3D microphysiological systems
  • Exploring common drug development issues to frame specific questions and highlighting how 3D tumour models can address these
  • Illustrating case studies of how Novartis are using microphysiological systems in current projects and future plans

9:40 am Speed Networking & Morning Refreshments

10:55 am MASTERMIND BREAKOUT: How, When, Where?! Selecting and Choosing the Right 3D System

Synopsis

Picking up on the morning’s presentation, this session acts as an opportunity to drive your own learning, crowdsource ideas and discover multiple perspectives for driving the internal confidence in 3D. Over the hour, each breakout will discuss the below questions. Feedback from each group will collated and presented morning of conference day 2.

  • Where should 3D models be qualified and successfully integrated into the R&D paradigm?
  • What are the remaining challenges that are yet to be addressed for integration of these models?
  • Where have 3D Models failed to exact their promise?
  • What are the pitfalls of classical animal models that 3D models are fulfilling?

11:40 am
Strategies For Understanding & Targeting The Microenviroment

11:40 am Utilizing Multicellular 3D Models for Preclinical Drug Discovery

  • Anita Seshire Head of Laboratory Cellular Pharmacology & Translational Innovation Platform Oncology , EMD Serono

Synopsis

  • Developing primary 3D cell cultures from patient material
  • Addition of monocytes or fibroblasts to identify a potential trophic role
  • Transplantation of multicellular spheres to create tumours with microenvironments and enable the exploration of the influence of the TME on stemness

12:10 pm Using Microfluidics to Evaluate Interactions Between Patient-Derived Tissues & Immune Components

12:40 pm Lunch & Networking

1:40 pm Using 3D Models to Investigate Mechanisms of Relieving Suppression of TME

  • William Hastings Exploratory ImmunoOncology Investigator , Novartis Institute of Biomedical Research

Synopsis

  • Performing compound profiling of targeted IO combination therapies in 3D models to aid in-vitro in-vivo translation
  • Analyzing immune suppressive features of co-culture
  • Highlighting the applications of co-culture to profiling targeted therapies using multiple readouts

2:10 pm Panel Discussion: Incorporating the Immune Component – Requirements for IO Models When Mimicking the Microenvironment in a Dish

Synopsis

  • What are the limitations to IO & where do you draw the line for their utility?
  • How do we avoid biasing model design and ensure that these systems are representative of patient responses?
  • To what degree of complexity should we align models to human-TME complexity?
  • Can we ever accurately model ME effects in a dish?
  • How can we overcome the current challenges of incorporating the immune and stromal components?

2:55 pm Afternoon Refreshments

3:55 pm Roundtable Discussions:

Synopsis

4:45 pm Round Table – Moderator Feedback

5:00 pm Close of Conference Day One

5:10 pm Drinks & Poster Reception

Synopsis

After the formal presentations have finished, the learning and networking carries on. The Poster Session is an informal part of the conference agenda, allowing you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships. During this session scientific posters will be presented on 3D models validating innovative targets, disease models highlighting novel mechanisms, systems that are informing investigative toxicology and safety assessments.